Opinion of the Transparency Council – cyclophosphamidum
At its meeting on 9 December 2024, the Transparency Council adopted opinion No. 199/2024 on the inclusion in reimbursement of medicines containing the active substance cyclophosphamidum in the scope of indications for use or dosage or mode of administration different from those specified in the Summary of Product Characteristics, i.e. autoimmune diseases, amyloidosis